We have located links that may give you full text access.
The MIC distribution of dalbavancin differs between different coagulase-negative staphylococci.
JAC-antimicrobial resistance. 2024 April
BACKGROUND: CoNS constitute a significant part of the human microbiota of skin and mucous membranes. They can cause nosocomial infections, and have shown decreased susceptibility to several antibiotics. The few remaining treatment options include (lipo)glycopeptides such as dalbavancin. However, there is a lack of knowledge concerning whether susceptibility to lipoglycopeptides varies between different species of CoNS.
OBJECTIVES: To determine the susceptibility to dalbavancin in different species of CoNS.
METHODS: We investigated 480 bacterial isolates from 10 CoNS species: Staphylococcus epidermidis , Staphylococcus capitis , Staphylococcus caprae , Staphylococcus haemolyticus , Staphylococcus lugdunensis , Staphylococcus warneri , Staphylococcus pettenkoferi , Staphylococcus hominis , Staphylococcus sciuri and Staphylococcus simulans . The isolates were randomly selected from different sources of infection, including blood isolates, as well as deep and superficial infections. Antibiotic susceptibility was tested with the gradient test method.
RESULTS: There was a statistically significant difference (ANOVA; P < 0.0001) in the MIC distribution for dalbavancin between different CoNS species. S. sciuri was the least susceptible species, with 90% of the isolates having an MIC value for dalbavancin above the EUCAST breakpoint of 0.125 mg/L. The lowest MIC90 values were seen for S. capitis , S. simulans and S. caprae (all 0.032 mg/L).
CONCLUSIONS: This study demonstrated a difference in dalbavancin susceptibility between different CoNS species, suggesting that species-specific breakpoints for CoNS should be further investigated.
OBJECTIVES: To determine the susceptibility to dalbavancin in different species of CoNS.
METHODS: We investigated 480 bacterial isolates from 10 CoNS species: Staphylococcus epidermidis , Staphylococcus capitis , Staphylococcus caprae , Staphylococcus haemolyticus , Staphylococcus lugdunensis , Staphylococcus warneri , Staphylococcus pettenkoferi , Staphylococcus hominis , Staphylococcus sciuri and Staphylococcus simulans . The isolates were randomly selected from different sources of infection, including blood isolates, as well as deep and superficial infections. Antibiotic susceptibility was tested with the gradient test method.
RESULTS: There was a statistically significant difference (ANOVA; P < 0.0001) in the MIC distribution for dalbavancin between different CoNS species. S. sciuri was the least susceptible species, with 90% of the isolates having an MIC value for dalbavancin above the EUCAST breakpoint of 0.125 mg/L. The lowest MIC90 values were seen for S. capitis , S. simulans and S. caprae (all 0.032 mg/L).
CONCLUSIONS: This study demonstrated a difference in dalbavancin susceptibility between different CoNS species, suggesting that species-specific breakpoints for CoNS should be further investigated.
Full text links
Related Resources
Trending Papers
Interstitial Lung Disease: A Review.JAMA 2024 April 23
Review article: Recent advances in ascites and acute kidney injury management in cirrhosis.Alimentary Pharmacology & Therapeutics 2024 March 26
Executive Summary: State-of-the-Art Review: Unintended Consequences: Risk of Opportunistic Infections Associated with Long-term Glucocorticoid Therapies in Adults.Clinical Infectious Diseases 2024 April 11
Clinical practice guidelines on the management of status epilepticus in adults: A systematic review.Epilepsia 2024 April 13
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app